Nuvation Bio (NUVB) Q2 2025 earnings summary

Executive summary

• Achieved FDA approval and U.S. launch of IBTROZI (taletrectinib) for ROS1-positive NSCLC in June 2025, marking transition to commercial-stage operations; also approved in China and under review in Japan.

• IBTROZI rapidly added as a Preferred Agent in NCCN guidelines, supporting strong early adoption and payer coverage.

• Early commercial momentum with 70 patients on IBTROZI within seven weeks post-approval, prescriptions across all sales regions and major target accounts.

• Completed acquisition of AnHeart Therapeutics in April 2024, expanding pipeline and commercial reach.

• Pipeline progress includes safusidenib for IDH1 mutant glioma and NUV-1511 in phase I, with updates expected in H2 2025.

Financial highlights

• Total Q2 2025 revenue was $4.8 million, including $1.2 million in net product revenue from IBTROZI in the first 13 business days post-approval.

• Net loss for Q2 2025 was $59.0 million, or $(0.17) per share, compared to $462.5 million in Q2 2024, which included a $425.1 million acquisition charge.

• Cash, cash equivalents, and marketable securities totaled $607.7 million as of June 30, 2025.

• R&D expenses were $27.4 million; SG&A expenses were $38.5 million, reflecting commercial buildout and one-time stock compensation charges.

• Secured $200 million in non-dilutive financing post-approval, with an additional $50 million available.

Outlook and guidance

• Expects patient uptake rate to accelerate, with early August showing an increase to about three new patients per business day.

• Will provide quarterly updates on new and continuing IBTROZI patients as a key metric.

• Anticipates additional royalty revenue from Japan and further pipeline data disclosures later in the year.

• Existing cash and investments expected to fund operations for at least the next 12 months.

• Ongoing clinical development and regulatory submissions for pipeline assets, with updates expected in H2 2025.